Editorial: Adaptive immune resistance in cancer therapy

Aimin Jiang; Ouyang Chen; Zhigang Liu; Hongzhou Cai; Linhui Wang; Lin Qi

doi:10.3389/fphar.2023.1277902

Editorial: Adaptive immune resistance in cancer therapy

Front Pharmacol. 2023 Aug 25:14:1277902. doi: 10.3389/fphar.2023.1277902. eCollection 2023.

Authors

Aimin Jiang¹, Ouyang Chen², Zhigang Liu³, Hongzhou Cai⁴, Linhui Wang¹, Lin Qi^{5

6}

Affiliations

¹ Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
² Department of Cell Biology, Duke University Medical Center, Durham, NC, United States.
³ Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, Dongguan, Guangdong, China.
⁴ Department of Urology, Jiangsu Cancer Hospital and The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
⁵ Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁶ Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, Hunan, China.

No abstract available

Keywords: adaptive immune resistance; biomarker; immunotherapy; prognosis; tumour microenvironment (TME).

Publication types

Editorial

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Foundation of China (81902560, 81730073 and 81872074) and the Fundamental Research Funds for the Central Universities of Central South University (2023ZZTS0024).